Best Biopharma Outsourcing Companies in Maryland, United States
The 73 best Biopharma Outsourcing companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Precision Medicine Group.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founded | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Precision Medicine Group Provider of clinical research, development, and commercialization services for life sciences | $532M | 67 mo ago | 2,269 2,269 → 3,563 (+57%) | 2012 | Late Stage | WordPressApple iCloud MailMicrosoft 365+42 | 63 patents Gene expression‑based biomarker diagnostics for disease prognosis and therapy selection | — |
| 2 | Pharmaceutics International CDMO focused on manufacturing pharmaceutical dosage forms | $171M | 27 mo ago | 248 248 → 348 (+40%) | 1994 | Acquired | WordPressMySQLPHP+26 | 23 patents Advanced drug delivery formulations: self‑emulsifying, solid concentrates, tri‑molecular complexes. | — |
| 3 | Orgenesis Developer of cell and gene therapies for multiple disorders | $79M | 27 mo ago | 167 | 2008 | Public | FirebaseChart.jsAnimate.css+15 | 91 patents Cell-based therapeutics and bioprocessing for viral, ocular, and cancer treatments | — |
| 4 | ImQuest BioSciences Preclinical CRO providing infectious disease, cancer, and toxicology research services | $39M | 112 mo ago | 18 | 2004 | Funding Raised | — | — | — |
| 5 | Omnia Biologics Process development and manufacturing services for biologics | $24M | 49 mo ago | 120 | 2001 | Acquired | WordPress Block EditorElementorWordPress+30 | — | 1 partnership |
| 6 | ReveraGen Developer of steroids for treating Duchenne muscular dystrophy | $23M | 56 mo ago | — | 2008 | Funding Raised | — | — | — |
| 7 | Paragon Bioservices Biologics solutions provider, from development to finished product supply | $23M | 94 mo ago | 400 | 1990 | Acquired | — | — | — |
| 8 | GSSHealth Provider of data management, logistics and training services 60Innovation top 36%Funding top 42%Product top 46%Tech bottom 45% All 5 signals ▾Innovationtop 36% Fundingtop 42% Producttop 46% Techbottom 45% Globalbottom 33% Innovation: 12 product lines Funding: Raised $18.2M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $18M | 14 mo ago | — | 2009 | Funding Raised | — | — | — |
| 9 | Cerium CRO focusing on developing and commercialising of drugs for the treatment of orphan diseases | $11M | 58 mo ago | 3 | 2012 | Series A | — | — | — |
| 10 | Xceleron Analytical CRO with expertise in AMS (Accelerator Mass Spectrometry) technology | $10M | 172 mo ago | 25 | 1997 | Acquired | — | — | — |
| 11 | BioFactura Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $8M | 85 mo ago | 33 | 2004 | Series B | — | 46 patents Antiviral therapeutics and vaccine compositions for orthopoxvirus infection treatment | — |
| 12 | Accelovance Global CRO providing comprehensive clinical trial management and drug development services | $6M | 129 mo ago | 248 | 2005 | Acquired | — | — | — |
| 13 | Fina Biosolutions Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets | $3M | 20 mo ago | 8 | 2006 | Seed | — | 91 patents Efficient cytoplasmic production of soluble recombinant therapeutic proteins | — |
| 14 | Noble Life Sciences Preclinical contract research organization offering standard GLP and non-GLP services | $335K | 156 mo ago | 35 | 2010 | Seed | WordPressMySQLPHP+25 | — | 1 internship |
| 15 | Mesa Science Associates Provider of pre-clinical research, formulation development, and regulatory services | $311K | 46 mo ago | 5 | 2011 | Funding Raised | — | — | — |
| 16 | EchoGenesis Developer of epigenetic therapies focused on disease treatment and healthcare outcomes | $306K | 17 mo ago | — | 2024 | Funding Raised | — | — | — |
| 17 | BullFrog AI Develops AI based drug development and biopharmaceuticals | $200K | 74 mo ago | 11 | 2017 | Public | WordPress Block EditorWordPressApple iCloud Mail+35 | 61 patents Advanced spa water jet, illumination, and component sealing technologies | 1 job opening |
| 18 | Capital Biosciences Provider of cell and molecular biology-based products and services | $150K | 146 mo ago | 6 | 2006 | Funding Raised | — | — | — |
| 19 | In vitro ADMET In vitro ADMET laboratories enhancing drug development efficiency through contract research | $100K | 177 mo ago | 2 | 2004 | Acquired | — | — | — |
Top 12 Biopharma Outsourcing companies in Maryland
#1
Funding Raised · Baltimore, Maryland · founded 2009$18.2Mraised▾
Provider of data management, logistics and training services
- Apr 2025Grant (prize money)$4.8M
- Apr 2025Grant (prize money)$2.2M
- Feb 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$250K
#2
Acquired · Hunt Valley, Maryland · founded 1994 · 248 employees$171.2Mraised▾
CDMO focused on manufacturing pharmaceutical dosage forms
- Mar 2024Unattributed$11.2M
- Jun 2023Unattributed$6M
- Dec 2022Unattributed$3M
- Oct 2022Unattributed$9M
#3
Public · Germantown, Maryland · founded 2008 · 167 employees$79.4Mraised▾
Developer of cell and gene therapies for multiple disorders. The pipeline drugs include ORGCAR19for Lymphoma, MOTC for melanoma, RanTop HPV for Genital Warts, Anal Dysplasia for covid-19, Kyslecel for chronic pancreatitis, Cartil-S for Osteoarthritis, and others.
- Mar 2024Post IPO$2.3M
- May 2023Post IPO$5M
- Nov 2022Post IPO$30M
- Mar 2022Post IPO$14.8M
#4
Seed · Rockville, Maryland · founded 2006 · 8 employees$3Mraised▾
Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets. The company provides bioconjugation services and products, assisting vaccine manufacturers in creating affordable conjugate vaccines. Core expertise lies in conjugation chemistry, bioconjugation, and conjugate vaccines. They offer a range of services including conjugation, protein services, and analytical services like multi-angle light scattering and immunoassay design. Products include carrier proteins like CRM197 and functionalized dextrans, including amino, fluorescent, and custom dextrans. They focus on making vaccine technology accessible, particularly in emerging markets, and offer consulting services to the Biotech and Vaccine industry. They also provide specialty immunoreagents and resources to support vaccine development and production.
- Oct 2024Seed$3M
- Jan 2024Grant (prize money)$300K
- Jan 2024Grant (prize money)$297.8K
- Apr 2020Grant (prize money)$289.1K
#5
Late Stage · Bethesda, Maryland · founded 2012 · 2269 employees$532.2Mraised▾
Provider of clinical research, development, and commercialization services for life sciences. It offers biomarker-driven research and development, plus commercialization services from product launch through maturity. Services span clinical development, specialty labs, commercial consulting, market access, and medical communications. The organization integrates expertise in lab sciences, translational informatics, regulatory affairs, payer insights, and marketing communications.
- Nov 2020PE—
- Feb 2019PE$32.2M
- Dec 2017PE$275M
- Dec 2015PE$75M
#6
Funding Raised · Bethesda, Maryland · founded 2024$305.6Kraised▾
Developer of epigenetic therapies focused on disease treatment and healthcare outcomes. The company is dedicated to advancing medicine through research in epigenetics. It aims to address a range of health conditions by leveraging epigenetic regulation.
- Jan 2025Grant (prize money)$305.6K
#7
Acquired · Rockville, Maryland · founded 2001 · 120 employees$23.9Mraised▾
Omnia was offering manufacturing and process development services for biologics developers. The company had both non-GMP and GMP facilities for process development from preclinical to Phase I/II manufacture. They had experience in working with adenovirus, lentivirus, retrovirus, AAV, VLP, and other viral platforms. Their services included manufacturing, process development, cell and virus banking and aseptic filling. The company is currently not accepting orders and is diverting them to Vigene Biosciences.
- May 2022Series B$23.9M
- May 2006Seed$1.5M
#8
Funding Raised · Rockville, Maryland · founded 2008$23.3Mraised▾
ReveraGen is a developer of steroids for treating Duchenne muscular dystrophy. It is a drug development company engaged in the discovery and development of proprietary therapeutic products for neuromuscular diseases such as Duchenne muscular dystrophy (DMD). Its lead product Vamorolone is a steroidal-type anti-inflammatory is being developed for the treatment of DMD.
- Sep 2021Grant (prize money)$1.2M
- Sep 2021Grant (prize money)$1.2M
- Nov 2020Grant (prize money)$3.3M
- Aug 2019Grant (prize money)$286.1K
#9
Funding Raised · Frederick, Maryland · founded 2004 · 18 employees$38.7Mraised▾
Preclinical CRO providing infectious disease, cancer, and toxicology research services. They offer comprehensive contract research and development services to evaluate novel pharmaceutical products. Their expertise includes compound screening, drug target validation, mechanism of action studies, and toxicity evaluations. Services cover small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies, and vaccines. They provide specialized services in virology, microbiology, in vitro toxicology, immunology, molecular biology, and cancer testing and drug screening support. Custom assay development and outsourced research and development support are also available. They focus on accelerating research and development efforts for new products in the prevention and treatment of human disease.
- Jan 2017Grant (prize money)$6.7M
- Jun 2012Grant (prize money)$14.3M
- Jul 2010Grant (prize money)$1.9M
- Jun 2010Grant (prize money)$395.6K
#10
Series A · Gaithersburg, Maryland · founded 2012 · 3 employees$11.2Mraised▾
Developer of drugs for rare diseases designed to focus on the development of medicines for efficacious therapies for patients with unmet needs. The company's drugs helps to cure pediatric and ultra-orphan conditions with high therapeutic value, enabling patients of special categories to cure the ailment without any harmful side effects.
- Jul 2021Series A$8.9M
- May 2021Conventional Debt$1.9M
- Jun 2016Seed$2.3M
#11
Acquired · Baltimore, Maryland · founded 1990 · 400 employees$22.9Mraised▾
Biologics solutions provider, from development to finished product supply. Offers comprehensive, integrated solutions for biologics, with expertise and technologies to deliver therapies to patients. Services include analytical services, process development, CGMP manufacturing for drug substance and drug product, cell therapy, gene therapy, and plasmid DNA. Specializes in cell type solutions, specialty bioconjugates, bispecifics, mRNA vaccines, and oncolytic viruses. Technologies include cell line development platforms. Provides development, manufacturing, and analytical testing for gene therapies and next-generation vaccines. Offers process characterization, drug substance/product manufacturing, and fill/finish services. Focuses on helping companies develop treatments and supply them to patients.
- Aug 2018Series A—
- Aug 2018Series A$5M
- May 2017Series A$2.4M
- Aug 2015Series A$2M
#12
Series B · Frederick, Maryland · founded 2004 · 33 employees$7.8Mraised▾
Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs. The company develops and manufactures high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. Committed to fulfilling unmet global biomedical and national biodefense needs, it utilizes a novel biomanufacturing platform to rapidly generate stable products. The company's expertise is grounded in bioprocess development, scale-up, and manufacturing. It focuses on strategic and scientific endeavors, partnership building, fundraising, intellectual property maintenance, contract research and development, platform technology programs, and biopharmaceutical product development. The company also provides strategic perspectives and plans for the targeted deployment of resources and the designing of clinical trials.
- May 2019Series B$6M
- May 2016Series A$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Maryland is moving
A read on the academic research around Biotechnology in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 57 papers.
- University of Maryland, Baltimore25
- University of Maryland, College Park22
- University of Maryland, Baltimore County6
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center2
- Maryland Department of Health2
- Cell culture3
- Epithelium2
- Limiting2
- Bacillus thuringiensis2
- Cell2
- Prostate cancer2
- Recombinase Polymerase Amplification1
- Multiple displacement amplification1
- Loop-mediated isothermal amplification1
- Nucleic acid1
- Antibiotic resistance2
- Antimicrobial2
- Aquaculture1
- Population1
- Antibiotics1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.